April 21, 2015

A Frost & Sullivan report released Tuesday found the self-monitoring blood-glucose meter market is threatened by reimbursement pressure and technological advancements. 

April 17, 2015

The Food and Drug Administration earlier this week wanted consumers to stop using workout supplement Tri-Methyl Xtreme. 

April 14, 2015

ANI Pharmaceuticals banking on strong growth in generics. 

March 24, 2015

A new report by Shoppers Drug Mart and Great-West Life demonstrates the importance of pharmacist interventions in diabetes management.

February 26, 2015

Sanofi expands its portfolio of insulin therapy products with the introduction of the once-daily, long-acting Toujeo. 

February 18, 2015

Natural Product Solutions on Wednesday announced the launch of its new VirMax Blood Sugar Stabilization Formula.

February 3, 2015

Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Co. on Monday announced that the Food and Drug Administration has approved Glyxambi (empagliflozin/linagliptin) tablets. 

 

February 3, 2015

Afrezza, an inhaled insulin powder, is now available by prescription in U.S. retail pharmacies, Sanofi and MannKind Corp. announced. The drug is approved by the Food and Drug Administration to control high blood sugar in adults who have type 1 and type 2 diabetes.

 

January 20, 2015

LifeScan on Tuesday introduced the new OneTouch Verio Blood Glucose Monitoring System that helps people with diabetes better understand their results without any extra effort.

January 12, 2015

Perrigo Co. on Monday announced the launch of testosterone gel 1%, the therapeutic equivalent to Androgel 1% from AbbVie. 

January 8, 2015

Data from a recent patient satisfaction study conducted by J.D. Power has found that Bayer blood glucose meters ranked highest in overall satisfaction among patients with diabetes.

January 6, 2015

People with type 1 diabetes who intensively control their blood glucose early in their disease are likely to live longer than those who do not.

January 5, 2015

The Consumer Healthcare Products Association thanked President Obama for signing the Designer Anabolic Steroid Control Act into law last month.

December 22, 2014

Mylan has announced the U.S. launch of its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day and 0.1 mg/day (twice weekly), which is the generic version of Novartis' Vivelle-DOT.

December 17, 2014

Ipsen Biopharmaceuticals on Tuesday announced that Somatuline Depot (lanreotide) Injection 120 mg (referred to as Somatuline) was approved by the U.S. Food and Drug Administration for the treatment of gastroenteropancreatic neuroendocrine tumors.

December 17, 2014

PL Developments on Wednesday announced that it has added menopause relief supplement, EstroG-100, to its private-label portfolio.

December 16, 2014

Novartis on Tuesday received approval from the Food and Drug Administration for Signifor long-acting release (pasireotide) for injectable suspension, for intramuscular use. 

 

December 12, 2014

The Council for Responsible Nutrition on Thursday welcomed the passage of the Designer Anabolic Steroid Control Act of 2014, a measure that will protect consumers from potentially dangerous anabolic steroids falsely marketed as dietary supplements.

November 24, 2014

Endo on Monday announced the acquisition of rights to Natesto (testosterone nasal gel), a testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism. 

November 17, 2014

Four-in-10 U.S. adults are expected to develop Type 2 diabetes at some point in their lifetime, according to a new study published in The Lancet Diabetes & Endocrinology in August, suggesting that as many as 126 million consumers will be looking for treatment options, including self-monitoring their condition at home.

November 17, 2014

Earlier this year iHealth Lab launched iHealth Align, a mobile blood-glucose monitor that plugs directly into a smartphone, and displays and stores readings using the iHealth Gluco-Smart app. 

November 11, 2014

In recognition of American Diabetes Month in November, Price Chopper has developed food- and health-related programs to help promote awareness on the issues surrounding diabetes and the people who are impacted by the disease.

October 31, 2014

Diabetes treatment with a low-cost generic drug can have significant, positive implications for a patient's quality of life and medication cost, according to new research from CVS Health.

October 30, 2014

AstraZeneca on Thursday announced that the Food and Drug Administration approved Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily drug for the treatment of adults with Type 2 diabetes.